Samanta Salvi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6981334/publications.pdf Version: 2024-02-01

		471509	501196
31	1,175	17	28
papers	citations	h-index	g-index
31	31	31	2324
all docs	docs citations	times ranked	citing authors

SAMANTA SALVI

#	Article	IF	CITATIONS
1	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. Science Translational Medicine, 2015, 7, 312re10.	12.4	366
2	Cell-free DNA as a diagnostic marker for cancer: current insights. OncoTargets and Therapy, 2016, Volume 9, 6549-6559.	2.0	104
3	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget, 2016, 7, 37839-37845.	1.8	69
4	<i>GSTP1</i> Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Disease Markers, 2016, 2016, 1-6.	1.3	68
5	Genome-wide plasma DNA methylation features of metastatic prostate cancer. Journal of Clinical Investigation, 2020, 130, 1991-2000.	8.2	68
6	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 368-373.	1.9	64
7	Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study. BioMed Research International, 2013, 2013, 1-5.	1.9	48
8	Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Disease Markers, 2015, 2015, 1-6.	1.3	40
9	GSTP1 methylation in cancer: a liquid biopsy biomarker?. Clinical Chemistry and Laboratory Medicine, 2018, 56, 702-717.	2.3	40
10	The potential use of urine cell free DNA as a marker for cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1283-1290.	3.1	39
11	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nature Communications, 2017, 8, 1801.	12.8	36
12	Cell-free DNA detected by "liquid biopsy―as a potential prognostic biomarker in early breast cancer. Oncotarget, 2017, 8, 16642-16649.	1.8	29
13	Plasma AR status and cabazitaxel in heavilyÂtreated metastatic castration-resistant prostate cancer. European Journal of Cancer, 2019, 116, 158-168.	2.8	29
14	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	4.6	22
15	miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. OncoTargets and Therapy, 2016, 9, 2735.	2.0	21
16	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. Scientific Reports, 2018, 8, 15442.	3.3	21
17	Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 240.e1-240.e11.	1.6	20
18	Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. Journal of Translational Medicine, 2016, 14, 249.	4.4	16

SAMANTA SALVI

#	Article	IF	CITATIONS
19	Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. International Journal of Molecular Sciences, 2014, 15, 12458-12468.	4.1	13
20	Cell-Free DNA Integrity Analysis in Urine Samples. Journal of Visualized Experiments, 2017, , .	0.3	13
21	Carcinosarcoma of the prostate: case report with molecular and histological characterization. International Journal of Biological Markers, 2018, 33, 540-544.	1.8	12
22	CYP17A1 Polymorphisms and Clinical Outcome of Castration-Resistant Prostate Cancer Patients Treated with Abiraterone. International Journal of Biological Markers, 2016, 31, 264-269.	1.8	10
23	Longâ€ŧerm clinical impact of PSA surge in castrationâ€resistant prostate cancer patients treated with abiraterone. Prostate, 2017, 77, 1012-1019.	2.3	6
24	Urinary Cell-Free DNA: Isolation, Quantification, and Quality Assessment. Methods in Molecular Biology, 2019, 1909, 211-221.	0.9	6
25	Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer. Oncotarget, 2017, 8, 18811-18820.	1.8	6
26	Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer. Translational Cancer Research, 2016, 5, S803-S808.	1.0	5
27	Serum and Plasma Copy Number Detection Using Real-time PCR. Journal of Visualized Experiments, 2017, , .	0.3	3
28	Urinary Cell-Free DNA Integrity Analysis. Methods in Molecular Biology, 2021, 2292, 17-22.	0.9	1
29	Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR. Journal of Visualized Experiments, 2018, , .	0.3	0
30	Studying Copy Number Variations in Cell-Free DNA: The Example of AR in Prostate Cancer. Methods in Molecular Biology, 2019, 1909, 95-103.	0.9	0
31	Analysis of Copy Number Variation in Urine: c-Myc Evaluation Using a Real-Time PCR Approach. Methods in Molecular Biology, 2021, 2292, 49-56.	0.9	0